Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Systematic Review

Published on 14 Dec 2023

Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Songfei Han
Cuishan Guo
Zixuan Song
Ling Ouyang
Yizi Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1330877

3,649 views
5 citations

Correction

Published on 14 Dec 2023

Corrigendum: Advances in the roles of glycyrrhizic acid in cancer therapy

in Pharmacology of Anti-Cancer Drugs

Yuqian Zhang
Zixuan Sheng
Jing Xiao
Yang Li
Jie Huang
Jinjing Jia
Xiansi Zeng
Li Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1345663

1,269 views
13 citations

Mini Review

Published on 14 Dec 2023

Research progress of biomineralization for the diagnosis and treatment of malignant tumors

in Pharmacology of Anti-Cancer Drugs

Yulu Wu
Xun Pan
Huixu Xie
Lin Que
Xiufa Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1335019

1,987 views
4 citations

Original Research

Published on 14 Dec 2023

Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model

in Pharmacology of Anti-Cancer Drugs

Qianyu Jing
Quan Wan
Yujie Nie
Junqian Luo
Xiangyan Zhang
Lan Zhu
Huan Gui
Linzhao Li
Chenglv Wang
Shuanghui Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1286061

8,145 views
8 citations

Original Research

Published on 13 Dec 2023

Iberverin exhibits antineoplastic activities against human hepatocellular carcinoma via DNA damage-mediated cell cycle arrest and mitochondrial-related apoptosis

in Pharmacology of Anti-Cancer Drugs

Yuting Zhang
Jiao Du
Libo Jin
Liying Pan
Xiufeng Yan
Sue Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1326346

2,294 views
8 citations

Case Report

Published on 12 Dec 2023

Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review

in Pharmacology of Anti-Cancer Drugs

Shuting Zhou
Zhenyu Zhang
Xiaodong Feng
Chengjian Zhao
Lu Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1276788

2,008 views
2 citations

Original Research

Published on 12 Dec 2023

NOP58 induction potentiates chemoresistance of colorectal cancer cells through aerobic glycolysis as evidenced by proteomics analysis

in Pharmacology of Anti-Cancer Drugs

Feifei Wang
Bin Yu
Quanyong Yu
Guanglin Wang
Baokun Li
Ganlin Guo
Handong Wang
Hui Shen
Shujin Li
Chunling Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1295422

2,802 views
4 citations

Case Report

Published on 11 Dec 2023

Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N

in Pharmacology of Anti-Cancer Drugs

Na Li
Huihui Li
Ding Wang
Xiaoling Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1197163

1,992 views
1 citation

Original Research

Published on 11 Dec 2023

Effect of Danshen for improving clinical outcomes in patients with bladder cancer: a retrospective, population-based study

in Pharmacology of Anti-Cancer Drugs

Yi-Hsin Chen
Chih-Tsung Chen
Han-Ping Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1260683

2,911 views
4 citations

Review

Published on 08 Dec 2023

Recent progress in the role of endogenous metal ions in doxorubicin-induced cardiotoxicity

in Pharmacology of Anti-Cancer Drugs

Ni Zhou
Shanshan Wei
Taoli Sun
Suifen Xie
Jian Liu
Wenqun Li
Bikui Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1292088

4,569 views
10 citations

Original Research

Published on 07 Dec 2023

Discovery of potential WEE1 inhibitors via hybrid virtual screening

in Pharmacology of Anti-Cancer Drugs

Tingting Jin
Wei Xu
Roufen Chen
Liteng Shen
Jian Gao
Lei Xu
Xinglong Chi
Nengming Lin
Lixin Zhou
Zheyuan Shen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1298245

3,727 views
2 citations

Retraction

Published on 07 Dec 2023

Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin

in Pharmacology of Anti-Cancer Drugs

Frontiers Editorial Office

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1349235

2,187 views
1 citation

Mini Review

Published on 07 Dec 2023

Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications

in Pharmacology of Anti-Cancer Drugs

Alan Jhones Barbosa Assis
Brunna Letícia de Oliveira Santana
Ana Cristina Moura Gualberto
Fabio Pittella-Silva

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1322937

9,584 views
6 citations

Original Research

Published on 07 Dec 2023

PdMo nanoflowers for endogenous/exogenous-stimulated nanocatalytic therapy

in Pharmacology of Anti-Cancer Drugs

Xinqiang Liang
Yanping Tang
Mekhrdod S. Kurboniyon
Danni Luo
Guiwan Tu
Pengle Xia
Shufang Ning
Litu Zhang
Chen Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1324764

1,710 views
3 citations

Original Research

Published on 06 Dec 2023

Preparation and investigation of a novel combination of Solanum nigrum-loaded, arabinoxylan-cross-linked β-cyclodextrin nanosponges for the treatment of cancer: in vitro, in vivo, and in silico evaluation

in Pharmacology of Anti-Cancer Drugs

Hamid Saeed Shah
Sumera Zaib
Imtiaz Khan
Mahmoud A. Sliem
Osama Alharbi
Mohammed Al-Ghorbani
Zobia Jawad
Kiran Shahzadi
Sajjad Awan

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1325498

3,488 views
4 citations

Original Research

Published on 06 Dec 2023

Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors

in Pharmacology of Anti-Cancer Drugs

Teppei Takeshima
Noboru Mimura
Shun Aoki
Tomoki Saito
Jurii Karibe
Kimitsugu Usui
Shinnosuke Kuroda
Mitsuru Komeya
Yasushi Yumura

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1324339

1,790 views
2 citations